Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients

BACKGROUND: Dolutegravir is a powerful, well-tolerated integrase inhibitor with a high genetic barrier to resistance and may thus constitute the backbone of lightened regimens. METHODS: This was a monocentric, retrospective study. HIV-1-infected patients receiving dolutegravir as monotherapy (mDGV)...

Descripción completa

Detalles Bibliográficos
Autores principales: Gubavu, Camelia, Prazuck, Thierry, Niang, Mohamadou, Buret, Jennifer, Mille, Catherine, Guinard, Jérôme, Avettand-Fènoël, Véronique, Hocqueloux, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790618/
https://www.ncbi.nlm.nih.gov/pubmed/26712907
http://dx.doi.org/10.1093/jac/dkv430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790618/
https://www.ncbi.nlm.nih.gov/pubmed/26712907
http://dx.doi.org/10.1093/jac/dkv430

Ejemplares similares